StockNews.com Initiates Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report issued on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Performance

Shares of NASDAQ:TCON opened at $0.04 on Wednesday. TRACON Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $14.75. The company’s fifty day moving average is $0.09 and its two-hundred day moving average is $0.61. The stock has a market capitalization of $119,350.00, a price-to-earnings ratio of 0.01 and a beta of 1.43.

TRACON Pharmaceuticals (NASDAQ:TCON) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The company had revenue of $0.06 million for the quarter.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.